This isn't going to happen...

Quote

anonymous

Guest
It's looking like Teva will beat us to approval with their drug. And, after that happens the FDA will delay out approval...no need for fast track...to the back of the line we go. One drug, no pipeline...incredibly cheap with offers. I accepted but will almost certainly decline IF this thing ever comes out. Too many risks, too few rewards.
 






not true

Teva drug inferior

I am not in sales. Some managers here are good. Some however don't truly know psych OR movement and are just along for ride. Mostly rural moms who are managers now and don't know anything. This cronyism ruined Avenir. Now it's Neurocrines turned for amateur hour. I know managers here that are good and see the true clueless nature of "leaders" brought in for this team. They are besides themselves.

If you have a job at over $100K base and should continue to be employed for more than a year, this place is not for you!
 






anonymous said:
It's looking like Teva will beat us to approval with their drug. And, after that happens the FDA will delay out approval...no need for fast track...to the back of the line we go. One drug, no pipeline...incredibly cheap with offers. I accepted but will almost certainly decline IF this thing ever comes out. Too many risks, too few rewards.
Click to expand...
Teva drug is for huntingtons chorea
 


















Teva's drug will be for HD ,but they also have an application in for TD. They are almost the same in efficacy and AE/s You can google the trials, I want to say they named their clinical trials ARM. The big issue is even if the Neurocrine drug comes out first Teva will still crush it. First they have relationships in Movement (TD is a movement disorder not a psych disorder) Second they are worth BILLIONS. They have a large generic side and make $$$$ to spend. Yes their MS side is not like it was, but still a powerhouse BE CAREFUL
 






Ok people do your research. Teva's drug is not much different then the Neurocrine preparation. They are brothers not identical twins. The two drugs were derived from Xenazine, a dopamine depleting agent sold by Lundbeck for HD. Teva submitted studies for HD and the FDA wanted more data so the indication is on hold/review. Teva and Neurocrine have both submitted and application for TD. Neurocrine applied first, and should be approved 4/11 Teva will follow with approval in late summer, early fall. If you google the studies for both drugs they were really the same in efficacy. If my memory is correct one dosage of the Teva drug was not statistically significant on the medium dosage,however all other dosages were. You can google the studies for their drug trials. I think they were named ARM studies. Teva have two big advantages. First they have relationships in movement (and BTW TD is a movement disorder not a psych issue) Second they are worth BILLIONS Yes their MS long acting drug is not doing so well, they have a big generic business, that is VERY profitable.
 






I am the same poster as the one above. I just did a little research and Teva should get approval on 4/3 for HD and late summer, early fall for TD The trials were name AIM.
 






Whoever is the poster that said "TD is not for psych" should really do their research. The #1 cause of TD is long term use of psychiatric drugs. Ask any psychiatrist and the #1 reason they are hesitant using atypicals of any kind is the potential for TD. Targeting psychs is by far the most business savvy area of opportunity for this drug. Additionally, they are getting an approval for Tourette's which again is a disorder treated by psychs. The reps will also be calling on a few neurologists and movement disorder specialists. Also, Teva's drug has a negative side effect profile which Neurocrine will easily be able to sell against.
 






I do not have a dog in this race, I am a retail pharmacist here is some food for thought. If Sally was on Abilify to augment her SSRI for depression. She stays the drug combo for two years and then is no longer depressed. She is no longer seeing a psych and six years later she TD presents. She will go see her GP/IM and will be sent to a neurologist. One other case, might be a 50 year old who was treated with Reglan some year back becomes dyskinectic. They will see their primary care physician and be sent on to a neurologist.

The last poster was correct in saying TD is caused mostly by antipsychotics. The first-generations (typical) are much worse(for TD) then the newer (atypical) neuroleptics, however Zyprexa and such still can bring on TD. One other thing to keep in mind is most of the patients who have been on long use of any type of neuroleptic usually are on some type of public assistance. You drug will be very pricey, and best of luck getting it approved.

I hope everything works out for you.
 






One note to the above poster regarding Sally. Even if she remains on the drug combo, but is no longer depressed, 9 out of 10 times she will continue to see her psych simply because most GM/IM's do not want to prescribe antipsychotics. Just like psych's reserve them for more severe symptoms, IM/GM docs don't want to go near the drugs and have the possible consequences on their prescription pad. Therefore, Sally will continue to see her psych for as long as she stays on the Abilify; depressed or not.
 






Top Bottom
Back
Quote